These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2307536)

  • 1. Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor.
    Loeffler DA; Keng PC; Baggs RB; Lord EM
    Int J Cancer; 1990 Mar; 45(3):462-7. PubMed ID: 2307536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.
    Moran JP; Gerber SA; Martin CA; Frelinger JG; Lord EM
    Int J Cancer; 2003 Sep; 106(5):690-8. PubMed ID: 12866028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model.
    Lord EM; Burkhardt G
    Cell Immunol; 1984 May; 85(2):340-50. PubMed ID: 6713544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.
    Lee J; Fenton BM; Koch CJ; Frelinger JG; Lord EM
    Cancer Res; 1998 Apr; 58(7):1478-85. PubMed ID: 9537251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy.
    Korbelik M; Krosl G; Krosl J; Dougherty GJ
    Cancer Res; 1996 Dec; 56(24):5647-52. PubMed ID: 8971170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
    Bizanek R; Chowdary D; Arai H; Kasai M; Hughes CS; Sartorelli AC; Rockwell S; Tomasz M
    Cancer Res; 1993 Nov; 53(21):5127-34. PubMed ID: 7693331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites.
    Shibamoto Y; Yukawa Y; Tsutsui K; Takahashi M; Abe M
    Jpn J Cancer Res; 1986 Sep; 77(9):908-15. PubMed ID: 3095287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures.
    Herman TS; Teicher BA; Collins LS
    Cancer Res; 1988 May; 48(9):2342-7. PubMed ID: 3356002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
    Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
    J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
    Pachynski RK; Wang P; Salazar N; Zheng Y; Nease L; Rosalez J; Leong WI; Virdi G; Rennier K; Shin WJ; Nguyen V; Butcher EC; Zabel BA
    Front Immunol; 2019; 10():983. PubMed ID: 31139180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages.
    Wilson KM; Siegal G; Lord EM
    Cell Immunol; 1989 Oct; 123(1):158-65. PubMed ID: 2776218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
    Woods ML; Koch CJ; Lord EM
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids.
    Franko AJ
    Radiat Res; 1985 Jul; 103(1):89-97. PubMed ID: 4070561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of the cytotoxic action of the mitomycin antibiotics in hypoxic and oxygenated EMT6 cells.
    Sartorelli AC; Tomasz M; Rockwell S
    Adv Enzyme Regul; 1993; 33():3-17. PubMed ID: 8356915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.
    Grosso JF; Herbert LM; Owen JL; Lopez DM
    J Immunol; 2004 Aug; 173(3):1721-30. PubMed ID: 15265901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.